Red blood cell transfusion use in patients with chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 28, Issue 6, 2013, Pages 1504-1515

  Gill, Karminder S ^a   Muntner, Paul ^b   Lafayette, Richard A ^c   Petersen, Jeffrey ^d   Fink, Jeffrey C ^e   Gilbertson, David T ^f   Bradbury, Brian D ^d,g  

^a Ascentiant International   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AMGEN INC   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allosensitization; Anemia management; Chronic kidney disease; Kidney transplantation; Red blood cell transfusion

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; IRON;

ADULT; AGE DISTRIBUTION; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; ERYTHROCYTE TRANSFUSION; FACTUAL DATABASE; FEMALE; HEALTH INSURANCE; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UNITED STATES;

ALLOSENSITIZATION; ANEMIA MANAGEMENT; CHRONIC KIDNEY DISEASE; KIDNEY TRANSPLANTATION; RED BLOOD CELL TRANSFUSION;

ADOLESCENT; ADULT; AGED; ANEMIA; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE; YOUNG ADULT;

EID: 84879863344     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs580     Document Type: Article

References (36)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
2. Obrador GT, Roberts T, St Peter WL et al. Trends in anemia at initiation of dialysis in the United States. Kidney Int 2001; 60: 1875-1884
3. Hsu CY. Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens 2002; 11: 337-341
4. McClellan W, Aronoff SL, Bolton WK et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501-1510
5. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int 1985; 28: 1-5
6. Astor BC, Muntner P, Levin A et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162: 1401-1408
7. Ibrahim HN, Ishani A, Guo H et al. Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older. Nephrol Dial Transplant 2009; 24: 3138-3143
8. Provenzano R, Garcia-Mayol L, Suchinda P et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004; 61: 392-405
9. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
10. Despotis GJ, Zhang L, Lublin DM. Transfusion risks and transfusion- related pro-inflammatory responses. Hematol Oncol Clin North Am 2007; 21: 147-161
11. Carson JL, Altman DG, Duff A et al. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion 1999; 39: 694-700
12. Epstein JS, Holmberg JA. Progress in monitoring blood safety. Transfusion 2010; 50: 1408-1412
13. Zou S, Dorsey KA, Notari EP et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495-1504
14. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739
15. Hardy S, Lee SH, Terasaki PI. Sensitization 2001. Clin Transpl 2001: 271-278
16. Karpinski M, Pochinco D, Dembinski I et al. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 2004; 15: 818-824
17. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570-1576
18. Ibrahim HN, Skeans MA, Li Q et al. Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes. Clin Transpl 2011; 25: 653-659
19. Lawler EV, Bradbury BD, Fonda JR et al. Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephro 2010; 5: 667-672
20. Walker AM, Bohn RL, Cali C et al. Risk factors for colon ischemia. Am J Gastroenterol 2004; 99: 1333-1337
21. Velentgas P, West W, Cannuscio CC et al. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin nonsteroidal anti-inflammatory medications. Pharmacoepidemiol Drug Saf 2006; 15: 641-652
22. USRDS. USRDS 2010 Annual Data Report: Atlas of Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, 2010
23. Hebert PL, Geiss LS, Tierney EF et al. Identifying persons with diabetes using Medicare claims data. Am J Med Qual 1999; 14: 270-277
24. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
25. Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387
26. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004; 23: 2109-2123
27. Balasubramaniam GS, Morris M, Gupta A et al. Allosensitization rate of male patients awaiting first kidney grafts after leuko-depleted blood transfusion. Transplantation 2012; 93: 418-422
28. Yabu J, Anderson M, Kim D et al. RBC transfusions are associated with human leukocyte antigen (HLA) allosensitization in patients awaiting kidney transplantation. In: American Society of Nephrology Annual Meeting 2011, San Diego
29. Aalten J, Bemelman FJ, van den Berg-Loonen EM et al. Prekidney- transplant blood transfusions do not improve transplantation outcome: a Dutch national study. Nephrol Dial Transplant 2009; 24: 2559-2566
30. Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. http://www. kidney.org/professionals/kdigo/ guidelines-anemia/cpr34.html. (Accessed 14 December 2011, date last accessed)
31. Scornik JC, Meier-Kriesche HU. Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention. Am J Transplant 2011; 11: 1785-1791
32. Ibrahim HN, Ishani A, Foley RN et al. Temporal trends in red blood transfusion among US dialysis patients, 1992-2005. Am J Kidney Dis 2008; 52: 1115-1121
33. Collins AJ, Guo H, Gilbertson DT et al. Predictors of ESA use in the non-dialysis chronic kidney disease population with anemia. Nephron Clin Pract 2009; 111: c141-c148
34. Lawler EV, Gagnon DR, Fink J et al. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration. Nephrol Dial Transplant 2010; 25: 2237-2244
35. Seliger S, Fox KM, Gandra SR et al. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study. Clin J Am Soc Nephro 2010; 5: 882-888
36. Winkelmayer WC, Liu J, Chertow GM et al. Predialysis nephrology care of older patients approaching end-stage renal disease. Arch Intern Med 2011; 171: 1371-1378